XXII Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 0.09
- P/S (TTM)
- 0.31
- EV/EBITDA
- -0.47
Profitability & growth
- ROE (TTM)
- -103.6%
- Operating margin
- -235.8%
- Revenue growth YoY
- -43.3%
- Dividend yield
- —
- Beta
- 0.60
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About 22nd Century Group Inc
Company profile22nd Century Group Inc (Ticker: XXII) is a pioneering biopharmaceutical and agricultural firm focused on tobacco harm reduction via advanced genetic engineering. The company is committed to developing low-nicotine tobacco products to mitigate nicotine addiction, thereby promoting better public health outcomes. In addition to its core focus, 22nd Century is strategically expanding into the rapidly evolving hemp and cannabis markets, positioning itself favorably within the burgeoning legal cannabis industry. With a strong emphasis on scientific research and regulatory compliance, 22nd Century…
Classification
- Sector
- Consumer Defensive
- Industry
- Tobacco
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 321 FARMINGTON ROAD, MOCKSVILLE, NC
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
